Santo Domingo · Dominican Republic

Foundational science, engineered for deployment

Three platforms in fields where incremental improvement is no longer enough: how proteins are purified, how bacterial infection is controlled, and how mass is moved against gravity.

Granted · MX 433331 Granted · JP 7768769 Pending · USPTO Prototype · Gravity platform

Three technologies, one mission

Sustainable innovation across energy, food, and health

01 / Energy & Mobility

Gravity, Reimagined

Patent-pending laser-based gravitational field modulation, in development for levitating transport, clean energy lift, and aerospace propulsion.

Gravity-Modulating Laser Technology

03 / Health

Post-Antibiotic Protection

Lysozyme, chelation, and a pH-stabilized formulation that kills bacteria without applying the selective pressure that breeds resistance.

Universal Bactericide

The mechanism

Why resistance does not develop

Antibiotics interfere with a metabolic pathway, so any mutation that routes around that pathway survives and propagates. This platform does not compete with bacterial metabolism at all.

  1. The chelating agent strips the divalent cations that hold the gram-negative outer membrane together.
  2. That exposes the peptidoglycan layer normally shielded from enzymatic attack.
  3. Lysozyme cleaves the peptidoglycan directly, and the cell fails structurally.
  4. The pH-stabilizing salt keeps the system active under physiological conditions.
Schematic · non-antibiotic bactericidal mechanism

Clinical evidence · dental indication

Measured against the reference antiseptic

A comparative study of 70 subjects, included in patent MX 433331, set the experimental formulation against chlorhexidine 0.12%.

0Gingival index at end of study, against above 0.5 in almost half of chlorhexidine subjects
14Days to zero recorded bleeding sites
75%Of treated cases with gingival inflammation minimized
0Adverse events attributable to the formulation
Unpleasant taste was reported by 14% in the extraction group, against 88% for chlorhexidine. Taste perception was unaltered in 0% of experimental cases. Comparative clinical study · n=70 · patent MX 433331
Dr. Diógenes Aybar, founder and lead researcher at Aybar Ecotechnologies

The founder

Dr. Diógenes Aybar

Member of the Academia de Ciencias de la República Dominicana, and the named inventor on every granted and pending patent in the portfolio. His work spans enzymology and protein chemistry, where the Aybar Protocol originated, and theoretical physics, where the EMG Theory of the Photon originated.

The theory was published in 1992. The company exists to carry it, and the chemistry that came with it, into the hands of people who can build with it.

  • 1992EMG Theory of the Photon published
  • 2Patents granted, Mexico and Japan
  • 3Platforms in active development

Read the founder’s full background →

Licensing & partnerships

Work with us on what comes next

Aybar Ecotechnologies works through licensing, joint ventures, and equity structures. Request the investor brief for a specific platform, or schedule a technical demonstration with our research team.